SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on January 9, 2003; DOI 10.1182/blood-2002-07-1952. This Article Full Text (PDF) All Versions of this Article: 2002-07-1952v1 101/9/3413    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Faderl, S. Articles by Keating, M. J Search for Related Content PubMed PubMed Citation Articles by Faderl, S. Articles by Keating, M. J Social Bookmarking                   What's this? Submitted July 2, 2002 Accepted November 1, 2002 Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Stefan Faderl*, Deborah A Thomas, Susan O'Brien, Guillermo Garcia-Manero, Hagop M Kantarjian, Francis J Giles, Charles Koller, Alessandra Ferrajoli, Srdan Verstovsek, Barbara Pro, Michael Andreeff, Miloslav Beran, Jorge Cortes, William Wierda, Ngoc Tran, and Michael J Keating Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA * Corresponding author; email: sfaderl{at}mdanderson.org. We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed/refractory lymphoid malignancies. Forty-eight patients have been treated and are assessable for response (32 CLL, 9 CLL/PLL, 1 PLL, 4 mantle cell leukemia/lymphoma, 2 Richter's transformation). The overall response rate was 52% (CR 8%, nPR 4%, PR 40%). With a median follow up of 6.5 months (range 1-20 months), the median time to progression is 6 months (range 1-20), and median survival 11 months (11+ months for responders versus 6 months for non-responders). Most toxicities were grade 2 and infusion-related. Infections occurred in 52% of the patients. CMV antigenemia was positive in 27%, but only 15% of the patients were symptomatic requiring therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a poor prognosis group of patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K Hodby and P A Fields Management of lymphoma in pregnancy Obstet Med, June 1, 2009; 2(2): 46 - 51. [Abstract] [Full Text] [PDF] M. A. Dimopoulos, M. A. Gertz, E. Kastritis, R. Garcia-Sanz, E. K. Kimby, V. LeBlond, J.-P. Fermand, G. Merlini, P. Morel, E. Morra, et al. Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia J. Clin. Oncol., January 1, 2009; 27(1): 120 - 126. [Abstract] [Full Text] [PDF] M. N. Dworzak, A. Schumich, D. Printz, U. Potschger, Z. Husak, A. Attarbaschi, G. Basso, G. Gaipa, R. Ratei, G. Mann, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy Blood, November 15, 2008; 112(10): 3982 - 3988. [Abstract] [Full Text] [PDF] H. Brenner, A. Gondos, and D. Pulte Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century Blood, May 15, 2008; 111(10): 4916 - 4921. [Abstract] [Full Text] [PDF] P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia J. Clin. Oncol., December 10, 2007; 25(35): 5616 - 5623. [Abstract] [Full Text] [PDF] V. A. Morrison Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia Hematology, January 1, 2007; 2007(1): 332 - 338. [Abstract] [Full Text] [PDF] S. Faderl, A. Ferrajoli, W. G. Wierda, S. O'Brien, F. Ravandi-Kashani, L. Fayad, D. Thomas, H. Kantarjian, M. L. Browning RN, and M. J. Keating MB The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2827 - 2827. [Abstract] [PDF] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch How I treat refractory CLL Blood, February 15, 2006; 107(4): 1276 - 1283. [Abstract] [Full Text] [PDF] J. C. Wade Viral Infections in Patients with Hematological Malignancies Hematology, January 1, 2006; 2006(1): 368 - 374. [Abstract] [Full Text] [PDF] B. L. Abbott Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Oncologist, January 1, 2006; 11(1): 21 - 30. [Abstract] [Full Text] [PDF] F. Ravandi and S. O'Brien Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., December 1, 2005; 80(12): 1660 - 1674. [Abstract] [PDF] S. Faderl, A. Ferrajoli, W. Wierda, F. Ravandi, S. O'Brien, G. Garcia-Manero, D. A. Thomas, M. L. Browning, and M. J. Keating Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 2963 - 2963. [Abstract] W. G. Wierda, T. J. Kipps, and M. J. Keating Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6325 - 6332. [Abstract] [Full Text] [PDF] R. R. Razonable Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients Am. J. Health Syst. Pharm., April 15, 2005; 62(suppl_1): S7 - S13. [Abstract] [Full Text] [PDF] M. Hallek and On Behalf Of The German CLL Study Group Chronic Lymphocytic Leukemia (CLL): First-Line Treatment Hematology, January 1, 2005; 2005(1): 285 - 291. [Abstract] [Full Text] [PDF] A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF] T. D. Shanafelt and T. G. Call Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia Mayo Clin. Proc., March 1, 2004; 79(3): 388 - 398. [Abstract] [PDF] M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells Blood, March 1, 2004; 103(5): 1763 - 1769. [Abstract] [Full Text] [PDF] J. C. Byrd, S. Stilgenbauer, and I. W. Flinn Chronic Lymphocytic Leukemia Hematology, January 1, 2004; 2004(1): 163 - 183. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020